Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: a nationwide population-based study
In patients with ILD-NSCLC, ICIs were associated with significantly longer OS compared with cytotoxic chemotherapy, despite the increased risk of DIILD.
Authors
- Hironao Hozumi (ORCID: https://orcid.org/0000-0001-5439-1543)
- Kazuki Furuhashi (ORCID: https://orcid.org/0000-0003-1167-5380)
- Naoki Inui (ORCID: https://orcid.org/0000-0002-4624-7119)
- Masato Karayama (ORCID: https://orcid.org/0000-0003-0455-4070)
- Yuzo Suzuki (ORCID: https://orcid.org/0000-0001-6154-9791)
- Noriyuki Enomoto (ORCID: https://orcid.org/0000-0003-3187-4264)
- Yusuke Inoue (ORCID: https://orcid.org/0000-0003-4298-9737)
- Takafumi Suda (ORCID: https://orcid.org/0000-0001-5300-0504)
- Hideki Yasui (ORCID: https://orcid.org/0000-0002-7134-3364)
- Tomoyuki Fujisawa (ORCID: https://orcid.org/0000-0002-8809-1781)
- Koichi Miyashita (ORCID: https://orcid.org/0000-0003-3550-1182)
Institutions
- Hamamatsu University School of Medicine (JP)
Publication Details
- Journal
- Thorax
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1136/thorax-2025-223430
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00